Frederick M. Schnell

777 total citations
17 papers, 481 citations indexed

About

Frederick M. Schnell is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Frederick M. Schnell has authored 17 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Frederick M. Schnell's work include Cancer Treatment and Pharmacology (3 papers), Lung Cancer Research Studies (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). Frederick M. Schnell is often cited by papers focused on Cancer Treatment and Pharmacology (3 papers), Lung Cancer Research Studies (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). Frederick M. Schnell collaborates with scholars based in United States, Switzerland and Australia. Frederick M. Schnell's co-authors include Ian D. Davis, Stephen Clarke, John D. Hainsworth, John Gutheil, Lee S. Rosen, Urte Gayko, John Zalcberg, Alessandra Cesano, Ehtesham Abdi and Kathleen J. Yost and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Frederick M. Schnell

17 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frederick M. Schnell United States 8 199 192 136 60 60 17 481
Aydın Yavuz Türkiye 10 81 0.4× 92 0.5× 130 1.0× 42 0.7× 40 0.7× 33 326
Winston Ueno United States 8 265 1.3× 197 1.0× 113 0.8× 19 0.3× 30 0.5× 13 531
Meng‐Hao Wu Taiwan 12 136 0.7× 116 0.6× 52 0.4× 18 0.3× 141 2.4× 18 390
Scott P. Tannehill United States 8 122 0.6× 163 0.8× 128 0.9× 114 1.9× 132 2.2× 15 464
Chih‐Long Chang Taiwan 14 157 0.8× 117 0.6× 45 0.3× 10 0.2× 136 2.3× 42 523
S. Malamud United States 12 242 1.2× 177 0.9× 128 0.9× 81 1.4× 4 0.1× 40 539
Birsen Yücel Türkiye 11 205 1.0× 64 0.3× 123 0.9× 57 0.9× 6 0.1× 53 362
Yu Min China 14 111 0.6× 125 0.7× 68 0.5× 5 0.1× 29 0.5× 49 519
Kathryn Monson United Kingdom 10 238 1.2× 111 0.6× 203 1.5× 84 1.4× 4 0.1× 15 519

Countries citing papers authored by Frederick M. Schnell

Since Specialization
Citations

This map shows the geographic impact of Frederick M. Schnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick M. Schnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick M. Schnell more than expected).

Fields of papers citing papers by Frederick M. Schnell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederick M. Schnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick M. Schnell. The network helps show where Frederick M. Schnell may publish in the future.

Co-authorship network of co-authors of Frederick M. Schnell

This figure shows the co-authorship network connecting the top 25 collaborators of Frederick M. Schnell. A scholar is included among the top collaborators of Frederick M. Schnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederick M. Schnell. Frederick M. Schnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Naik, Gurudatta, et al.. (2018). Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.. Journal of Clinical Oncology. 36(6_suppl). 224–224. 1 indexed citations
2.
Atri, Mostafa, Zheng Zhang, Farrokh Dehdashti, et al.. (2016). Utility of PET-CT to evaluate retroperitoneal lymph node metastasis in advanced cervical cancer: Results of ACRIN6671/GOG0233 trial. Gynecologic Oncology. 142(3). 413–419. 66 indexed citations
3.
Farooqi, Bilal, et al.. (2015). Racial disparities in breast cancer diagnosis in Central Georgia in the United States. The Journal of Community and Supportive Oncology. 13(12). 436–441. 5 indexed citations
4.
Overton, Lindsay, Christopher L. Corless, Manish Agrawal, et al.. (2014). Impact of next-generation sequencing (NGS) on treatment decisions in the community oncology setting.. Journal of Clinical Oncology. 32(15_suppl). 11028–11028. 1 indexed citations
5.
Schwartzberg, Lee S., L. Johnetta Blakely, Frederick M. Schnell, et al.. (2011). Abstract 4714: Phase I/II trial of ixabepilone (Ixa) and dasatinib (D) for treatment of metastatic breast cancer (MBC). Cancer Research. 71(8_Supplement). 4714–4714. 1 indexed citations
6.
Hainsworth, John D., Denise A. Yardley, David R. Spigel, et al.. (2006). Docetaxel and Epirubicin as First-Line Treatment for Patients with Metastatic Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial. Cancer Investigation. 24(5). 469–473. 6 indexed citations
7.
Rosen, Lee S., Ehtesham Abdi, Ian D. Davis, et al.. (2006). Palifermin Reduces the Incidence of Oral Mucositis in Patients With Metastatic Colorectal Cancer Treated With Fluorouracil-Based Chemotherapy. Journal of Clinical Oncology. 24(33). 5194–5200. 83 indexed citations
8.
Blakely, Johnetta, Frederick M. Schnell, Paul Kaywin, et al.. (2006). Phase II trial of pemetrexed (P) and gemcitabine (G) as first-line chemotherapy for elderly and/or poor performance status patients with stage IIIB/IV non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 24(18_suppl). 17031–17031. 4 indexed citations
9.
Hainsworth, John D., Anthony A. Meluch, Sharlene Litchy, et al.. (2005). Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 103(11). 2298–2303. 39 indexed citations
10.
11.
Vogel, Charles L., Ronald Yanagihara, Frederick M. Schnell, et al.. (2004). Safety and Pain Palliation of Zoledronic Acid in Patients with Breast Cancer, Prostate Cancer, or Multiple Myeloma Who Previously Received Bisphosphonate Therapy. The Oncologist. 9(6). 687–695. 63 indexed citations
12.
West, William H., et al.. (2003). Phase I Study of Paclitaxel and Topotecan for the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer. The Oncologist. 8(1). 76–82. 11 indexed citations
13.
Schnell, Frederick M.. (2003). Chemotherapy-Induced Nausea and Vomiting: The Importance of Acute Antiemetic Control. The Oncologist. 8(2). 187–198. 158 indexed citations
14.
Crawford, Jeffrey, et al.. (2000). A phase II multicycle trial of pegfilgrastim compared to Filgrastim after myelosuppressive chemotherapy. Lung Cancer. 29(1). 269–269. 3 indexed citations
15.
Atkins, James N., Hyman B. Muss, Douglas Case, et al.. (1991). High-Dose 24-Hour Infusion of 5-Fluorouracil in Metastatic Prostate Cancer. American Journal of Clinical Oncology. 14(6). 526–529. 23 indexed citations
16.
White, Dougľas R., Bayard L. Powell, Robert K. Stuart, et al.. (1990). A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A piedmont oncology association study. Cancer. 65(8). 1700–1703. 5 indexed citations
17.
Powell, Bayard L., John B. Craig, Hyman B. Muss, et al.. (1988). Phase II Trial of High-Dose Cytosine Arabinoside and Cisplatin in Recurrent Squamous Carcinoma of the Head and Neck A Piedmont Oncology Association Study. American Journal of Clinical Oncology. 11(5). 550–552. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aydın Yavuz Breakdown of academic impact, for papers by Winston Ueno Breakdown of academic impact, for papers by Meng‐Hao Wu Breakdown of academic impact, for papers by Scott P. Tannehill Breakdown of academic impact, for papers by Chih‐Long Chang Breakdown of academic impact, for papers by S. Malamud Breakdown of academic impact, for papers by Birsen Yücel Breakdown of academic impact, for papers by Yu Min Breakdown of academic impact, for papers by Kathryn Monson
Rankless by CCL
2026